Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 3632578)

Published in PLoS One on April 22, 2013

Authors

Thanyanan Chaowanachan1, Emily Krogstad, Cameron Ball, Kim A Woodrow

Author Affiliations

1: Department of Bioengineering, University of Washington, Seattle, Washington, United States of America.

Articles cited by this

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91

Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94

The search for synergy: a critical review from a response surface perspective. Pharmacol Rev (1995) 8.24

Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet (2011) 6.91

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49

Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol (2009) 4.73

The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials (2000) 4.42

Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS (2006) 4.23

In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One (2010) 4.08

HIV vaccine research: the way forward. Science (2008) 3.86

HIV/AIDS in women: an expanding epidemic. Science (2005) 3.68

A vaginal fluid simulant. Contraception (1999) 3.36

Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 3.25

Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol (1995) 3.15

Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J (2002) 3.13

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry (1998) 2.87

Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater (2009) 2.87

Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med (2008) 2.74

Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res (2003) 2.32

Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol (2008) 2.27

A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis (2005) 2.26

Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother (2007) 2.22

Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood (2006) 2.13

Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm (2004) 2.06

Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Res (2004) 1.91

Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci (2005) 1.77

NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) (2009) 1.72

A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med (2012) 1.68

Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol (2010) 1.42

Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs (1996) 1.35

P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol (2001) 1.30

Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release (2010) 1.28

Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother (2009) 1.26

Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol (2012) 1.23

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother (2010) 1.19

Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev (2009) 1.15

Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis (2009) 1.13

Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses (2001) 1.08

Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother (2010) 1.07

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology (2009) 1.05

Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus. Biomaterials (2011) 1.04

Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res (2010) 1.04

Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother (2011) 1.04

Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomedicine (2010) 1.04

Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol (2000) 1.04

Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res (2008) 1.04

Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm Res (2006) 0.99

Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. AIDS Res Hum Retroviruses (2007) 0.98

Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev (2009) 0.94

Sonication parameters for the preparation of biodegradable nanocapsules of controlled size by the double emulsion method. Pharm Dev Technol (2003) 0.92

Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation. Antimicrob Agents Chemother (2008) 0.92

A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles. J Control Release (2011) 0.90

Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm Res (2011) 0.86

Miniature device for aqueous and non-aqueous solubility measurements during drug discovery. Pharm Res (2004) 0.80

Nanotechnology and HIV: potential applications for treatment and prevention. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.79

Expression of ornithine decarboxylase during the transport of saquinavir across the blood-brain barrier using composite polymeric nanocarriers under an electromagnetic field. Colloids Surf B Biointerfaces (2011) 0.77

Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma. Clin Chem (2000) 0.77

HPLC quantification of the HIV-1 protease inhibitor saquinavir in brain and testis of mice. Biomed Chromatogr (2006) 0.77